search
Back to results

A Study of LXR015-1 in HIV-Infected Patients

Primary Purpose

HIV Infections

Status
Completed
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
LXR015-1
Sponsored by
LXR Biotechnology
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an interventional treatment trial for HIV Infections focused on measuring Dose-Response Relationship, Drug, Administration, Oral, Acquired Immunodeficiency Syndrome, Anti-HIV Agents

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria Patients must have: Documented HIV infection. CD4 cell count less than 200 cells/mm3. Prior Medication: Allowed: Acute therapy for opportunistic infections or serious AIDS defining infections must be completed at least 28 days before study entry. Exclusion Criteria Co-existing Condition: Patients with the following symptoms or conditions are excluded: Patients that are unable to take adequate oral intake (i.e. unable to eat 1 or more meals a day because of chronic nausea, emesis, or abdominal/oral/esophageal discomfort). Patients who have severe diarrhea as defined as >= 7 stools per day, or acute diarrhea due to a treatable cause. NOTE: If the patient has Cryptosporidia, Mycobacterium avium, or Cytomegalovirus that is unresponsive to treatment and has less than 7 stools per day, the patient may participate in this study. Patients who have any severe or life-threatening laboratory or clinical abnormality, or are not expected to live for 8 weeks. Patients who have an active opportunistic infection, including tuberculosis, cryptococcosis, or other serious AIDS defining infections requiring immediate treatment. Acute therapy must be completed at least 28 days before study entry. Patients with unexplained elevated temperature >= 38.5 degrees C that persists for 7 days or more within 14 days before study entry. Patients with malignancy other than squamous or basal carcinomas of the skin. Patients with visceral Kaposi's sarcoma or lymphoma requiring systemic chemotherapy or radiation treatment will be excluded. Patients with Kaposi's of the skin or mucous membranes may enroll in this study. Patients, who in the judgment of the investigator are unable to comply with the protocol. Concurrent Treatment: Excluded: Radiation therapy. Patients with the following prior condition are excluded: A known history of hypersensitivity reaction to soy protein or soy lecithin. NOTE: This hypersensitivity is identified through medical history, not skin testing. Excluded: Systemic chemotherapy. Acute therapy for opportunistic infections or other serious AIDS defining infections. Intravenous rehydration as treatment for diarrhea. Required: Patient must be taking a stable regimen (about 8 weeks) of anti-viral, anti-opportunistic infection and/or anti-diarrheal (if patient has diarrhea) medications.

Sites / Locations

  • East Bay AIDS Ctr

Outcomes

Primary Outcome Measures

Secondary Outcome Measures

Full Information

First Posted
November 2, 1999
Last Updated
June 23, 2005
Sponsor
LXR Biotechnology
search

1. Study Identification

Unique Protocol Identification Number
NCT00002365
Brief Title
A Study of LXR015-1 in HIV-Infected Patients
Official Title
A Randomized, Parallel, Open-Label Phase I Study of LXR015-1 in HIV-Infected Patients
Study Type
Interventional

2. Study Status

Record Verification Date
July 1998
Overall Recruitment Status
Completed
Study Start Date
undefined (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
undefined (undefined)

3. Sponsor/Collaborators

Name of the Sponsor
LXR Biotechnology

4. Oversight

5. Study Description

Brief Summary
To determine and compare the safety and tolerability of 3 doses of LXR015-1 in HIV-infected patients.
Detailed Description
Patients will be randomized to 1 of 3 doses of oral LXR015-1 for 28 days and patients will be monitored for adverse events for the duration of the study. Patients will continue to be monitored for least 4 weeks after completion of the dosing.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
HIV Infections
Keywords
Dose-Response Relationship, Drug, Administration, Oral, Acquired Immunodeficiency Syndrome, Anti-HIV Agents

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1
Masking
None (Open Label)
Enrollment
30 (false)

8. Arms, Groups, and Interventions

Intervention Type
Drug
Intervention Name(s)
LXR015-1

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria Patients must have: Documented HIV infection. CD4 cell count less than 200 cells/mm3. Prior Medication: Allowed: Acute therapy for opportunistic infections or serious AIDS defining infections must be completed at least 28 days before study entry. Exclusion Criteria Co-existing Condition: Patients with the following symptoms or conditions are excluded: Patients that are unable to take adequate oral intake (i.e. unable to eat 1 or more meals a day because of chronic nausea, emesis, or abdominal/oral/esophageal discomfort). Patients who have severe diarrhea as defined as >= 7 stools per day, or acute diarrhea due to a treatable cause. NOTE: If the patient has Cryptosporidia, Mycobacterium avium, or Cytomegalovirus that is unresponsive to treatment and has less than 7 stools per day, the patient may participate in this study. Patients who have any severe or life-threatening laboratory or clinical abnormality, or are not expected to live for 8 weeks. Patients who have an active opportunistic infection, including tuberculosis, cryptococcosis, or other serious AIDS defining infections requiring immediate treatment. Acute therapy must be completed at least 28 days before study entry. Patients with unexplained elevated temperature >= 38.5 degrees C that persists for 7 days or more within 14 days before study entry. Patients with malignancy other than squamous or basal carcinomas of the skin. Patients with visceral Kaposi's sarcoma or lymphoma requiring systemic chemotherapy or radiation treatment will be excluded. Patients with Kaposi's of the skin or mucous membranes may enroll in this study. Patients, who in the judgment of the investigator are unable to comply with the protocol. Concurrent Treatment: Excluded: Radiation therapy. Patients with the following prior condition are excluded: A known history of hypersensitivity reaction to soy protein or soy lecithin. NOTE: This hypersensitivity is identified through medical history, not skin testing. Excluded: Systemic chemotherapy. Acute therapy for opportunistic infections or other serious AIDS defining infections. Intravenous rehydration as treatment for diarrhea. Required: Patient must be taking a stable regimen (about 8 weeks) of anti-viral, anti-opportunistic infection and/or anti-diarrheal (if patient has diarrhea) medications.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Bathurst I
Official's Role
Study Chair
Facility Information:
Facility Name
East Bay AIDS Ctr
City
Berkeley
State/Province
California
ZIP/Postal Code
94705
Country
United States

12. IPD Sharing Statement

Learn more about this trial

A Study of LXR015-1 in HIV-Infected Patients

We'll reach out to this number within 24 hrs